Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige

BioVersys and partners to present AlpE data at The Union World Conference on Lung Health 11.11.2026, 07:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
BioVersys 23,90 CHF +5,75 % SIX Swiss (CHF)
Kostenlose Aktienchance per SMS Ausgewählte Trading-Einschätzungen aufs Handy.

BioVersys AG / Key word(s): Conference
BioVersys and partners to present AlpE data at The Union World Conference on Lung Health

11.11.2026 / 07:00 CET/CEST


Basel, Switzerland. November 11, 2026, 7.00am CEST

 

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that it will present new data on alpibectir together with its development partner GSK. The Union World Conference on Lung Health is taking place from 17 to 20 November 2026 in Rio de Janeiro, Brazil.

Presentations will include the latest Phase 2 data on alpibectir in combination with ethionamide (AlpE), in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.

The Union World Conference on Lung Health brings together researchers, practitioners, advocates, policymakers and communities from around the world to share knowledge, exchange ideas and accelerate progress in lung health.

 

Alpibectir data presentation schedule at the Union Conference

Date and time (BRT)

Presenter

Presentation

Session

Wednesday, 18 November
12:15–12:20

Dr. Simphiwe RN Simelane

E-poster: “Early bactericidal activity, safety, and pharmacokinetics of alpibectir–ethionamide in pulmonary tuberculosis”

EP16
Emerging therapeutics in TB safety, efficacy and early activity

Thursday, 19 November
09:58–10:06

Dr. Michel Pieren, BioVersys

“Alpibectir potentiates ethionamide and ethionamide-sulfoxide activity in M. tuberculosis clinical isolates from a Phase 2a study”

OA24
Alchemy: Dose determination, safety and adverse effects in preclinical and clinical TB trials

Thursday, 19 November
10:16–10:30

Dr. Simphiwe RN Simelane

“Early bactericidal activity, safety and PK of alpibectir-ethionamide in pulmonary tuberculosis: Results from the ENABLE trial”

SY08
Reimagining TB drug development: Phase 2 results from the UNITE4TB platform

Friday, 20 November
13:11–13:28

Dr. Simon Tiberi

“Early bactericidal activity, safety and PK of alpibectir-ethionamide and updates on further development of alpibectir-containing TB regimens”

SS12
Tackling tuberculosis today and for the future: From pipeline innovation to global collaboration

Satellite session: 12:15–13:45; chaired by David Barros-Aguirre

 

About BioVersys
BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.

About Alpibectir

Alpibectir (previously known as BVL-GSK098) is a small molecule developed from BioVersys’ award winning Transcriptional Regulatory Inhibitory Compounds (TRIC) platform in a successful collaboration with GSK, the Institut Pasteur Lille and the University of Lille. Alpibectir acts through a novel mode of action, potentiating the activity of the anti-TB drug ethionamide (Eto). Alpibectir is being studied for its potential to lower the efficacious human dose of Eto, minimizing of dose-dependent side effects, and overcome Eto resistance. The combination alpibectir/Eto (AlpE) is being developed for the treatment of pulmonary TB and TB meningitis. In 2023 AlpE was granted orphan-drug designation (ODD) for the treatment of tuberculosis, by the U.S. Food and Drug Administration (U.S. FDA) providing for certain incentives including seven years US market exclusivity. Similarly in 2025, AlpE was granted Orphan Designation from the European Medicines Agency (EMA), providing for certain incentives including 10-year EU market exclusivity.

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 

BioVersys contact 
Anca Cighi
, Head of IR and Communications, Tel. +41 79 949 33 09; Mail: anca.cighi@bioversys.com
For IR: IR@bioversys.com;  Website: www.bioversys.com



End of Media Release
View original content: EQS News


2432126  11.11.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer